2seventy Bio Inc (TSVT)

$4.29

+0.02

(+0.47%)▲

Market is closed - opens 7 PM, 26 Apr 2024

Insights on 2seventy Bio Inc

  • Decreasing Revenue

    Revenue is down for the last 5 quarters, 56.17M → 10.68M (in $), with an average decrease of 29.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -71.63M → -56.82M (in $), with an average increase of 26.1% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 52.5% return, outperforming this stock by 101.7%

Performance

  • $3.48
    $4.33
    $4.29
    downward going graph

    18.88%

    Downside

    Day's Volatility :19.63%

    Upside

    0.92%

    downward going graph
  • $1.54
    $12.69
    $4.29
    downward going graph

    64.1%

    Downside

    52 Weeks Volatility :87.86%

    Upside

    66.19%

    downward going graph

Returns

Period2seventy Bio IncSector (Health Care)Index (Russel 2000)
3 Months
33.23%
0.5%
0.0%
6 Months
68.24%
11.7%
0.0%
1 Year
-49.23%
6.2%
2.2%
3 Years
-87.24%
13.5%
-23.0%

Highlights

Market Capitalization
219.1M
Book Value
$5.04
Earnings Per Share (EPS)
-4.42
Wall Street Target Price
11.0
Profit Margin
-216.73%
Operating Margin TTM
-560.47%
Return On Assets TTM
-22.17%
Return On Equity TTM
-76.91%
Revenue TTM
100.4M
Revenue Per Share TTM
2.04
Quarterly Revenue Growth YOY
-81.0%
Gross Profit TTM
-183.5M
EBITDA
-206.4M
Diluted Eps TTM
-4.42
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.94
EPS Estimate Next Year
-0.7
EPS Estimate Current Quarter
-0.99
EPS Estimate Next Quarter
-0.7

Analyst Recommendation

Buy
    64%Buy
    35%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for 2seventy Bio Inc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
11
Hold
5
4
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 156.41%

Current $4.29
Target $11.00

Company Financials

FY18Y/Y Change
Revenue
54.6M
-
Net Income
-199.7M
-
Net Profit Margin
-365.98%
-
FY19Y/Y Change
Revenue
44.3M
↓ 18.84%
Net Income
-323.3M
↑ 61.87%
Net Profit Margin
-729.96%
↓ 363.98%
FY20Y/Y Change
Revenue
248.1M
↑ 460.15%
Net Income
-138.2M
↓ 57.27%
Net Profit Margin
-55.69%
↑ 674.27%
FY21Y/Y Change
Revenue
54.5M
↓ 78.03%
Net Income
-292.2M
↑ 111.49%
Net Profit Margin
-535.95%
↓ 480.26%
FY22Y/Y Change
Revenue
91.5M
↑ 67.81%
Net Income
-254.1M
↓ 13.03%
Net Profit Margin
-277.77%
↑ 258.18%
FY23Y/Y Change
Revenue
100.4M
↑ 9.72%
Net Income
-217.6M
↓ 14.39%
Net Profit Margin
-216.73%
↑ 61.04%
Q3 FY22Q/Q Change
Revenue
13.4M
↓ 0.55%
Net Income
-67.4M
↓ 12.89%
Net Profit Margin
-502.98%
↑ 71.27%
Q4 FY22Q/Q Change
Revenue
56.2M
↑ 318.98%
Net Income
-23.1M
↓ 65.68%
Net Profit Margin
-41.2%
↑ 461.78%
Q1 FY23Q/Q Change
Revenue
41.6M
↓ 25.91%
Net Income
-42.5M
↑ 83.53%
Net Profit Margin
-102.05%
↓ 60.85%
Q2 FY23Q/Q Change
Revenue
36.0M
↓ 13.39%
Net Income
-42.1M
↓ 0.91%
Net Profit Margin
-116.76%
↓ 14.71%
Q3 FY23Q/Q Change
Revenue
12.0M
↓ 66.62%
Net Income
-71.6M
↑ 70.21%
Net Profit Margin
-595.3%
↓ 478.54%
Q4 FY23Q/Q Change
Revenue
10.7M
↓ 11.22%
Net Income
-56.8M
↓ 20.68%
Net Profit Margin
-531.84%
↑ 63.46%
FY19Y/Y Change
Total Assets
314.9M
-
Total Liabilities
271.3M
-
FY20Y/Y Change
Total Assets
312.6M
↓ 0.74%
Total Liabilities
238.0M
↓ 12.26%
FY21Y/Y Change
Total Assets
759.7M
↑ 143.0%
Total Liabilities
399.9M
↑ 68.01%
FY22Y/Y Change
Total Assets
656.7M
↓ 13.56%
Total Liabilities
346.2M
↓ 13.42%
FY23Y/Y Change
Total Assets
565.4M
↓ 13.89%
Total Liabilities
310.1M
↓ 10.42%
Q3 FY22Q/Q Change
Total Assets
708.7M
↓ 9.99%
Total Liabilities
385.6M
↓ 5.6%
Q4 FY22Q/Q Change
Total Assets
656.7M
↓ 7.35%
Total Liabilities
346.2M
↓ 10.21%
Q1 FY23Q/Q Change
Total Assets
742.4M
↑ 13.06%
Total Liabilities
341.1M
↓ 1.47%
Q2 FY23Q/Q Change
Total Assets
705.7M
↓ 4.95%
Total Liabilities
338.2M
↓ 0.85%
Q3 FY23Q/Q Change
Total Assets
640.8M
↓ 9.2%
Total Liabilities
334.4M
↓ 1.13%
Q4 FY23Q/Q Change
Total Assets
565.4M
↓ 11.76%
Total Liabilities
310.1M
↓ 7.25%
FY18Y/Y Change
Operating Cash Flow
-146.2M
-
Investing Cash Flow
-50.8M
-
Financing Cash Flow
197.0M
-
FY19Y/Y Change
Operating Cash Flow
-208.0M
↑ 42.23%
Investing Cash Flow
-59.8M
↑ 17.59%
Financing Cash Flow
267.7M
↑ 35.87%
FY20Y/Y Change
Operating Cash Flow
-67.8M
↓ 67.4%
Investing Cash Flow
-22.3M
↓ 62.75%
Financing Cash Flow
90.1M
↓ 66.36%
FY21Y/Y Change
Operating Cash Flow
-207.0M
↑ 205.39%
Investing Cash Flow
15.4M
↓ 169.23%
Financing Cash Flow
354.9M
↑ 294.08%
FY22Y/Y Change
Operating Cash Flow
-237.1M
↑ 14.54%
Investing Cash Flow
11.7M
↓ 24.1%
Financing Cash Flow
166.2M
↓ 53.16%
Q3 FY22Q/Q Change
Operating Cash Flow
-60.9M
↑ 30.58%
Investing Cash Flow
-82.3M
↓ 265.34%
Financing Cash Flow
175.0K
↓ 104.09%
Q4 FY22Q/Q Change
Operating Cash Flow
-55.5M
↓ 8.94%
Investing Cash Flow
-532.0K
↓ 99.35%
Financing Cash Flow
232.0K
↑ 32.57%
Q1 FY23Q/Q Change
Operating Cash Flow
-49.1M
↓ 11.52%
Investing Cash Flow
44.8M
↓ 8520.68%
Financing Cash Flow
127.1M
↑ 54677.59%
Q2 FY23Q/Q Change
Operating Cash Flow
-32.7M
↓ 33.46%
Investing Cash Flow
-64.9M
↓ 244.83%
Financing Cash Flow
128.0K
↓ 99.9%

Technicals Summary

Sell

Neutral

Buy

2seventy Bio Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
2seventy Bio Inc
2seventy Bio Inc
-13.51%
68.24%
-49.23%
-87.24%
-87.24%
Moderna, Inc.
Moderna, Inc.
-1.15%
39.75%
-18.77%
-40.22%
304.34%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.56%
12.46%
14.48%
77.72%
159.17%
Novo Nordisk A/s
Novo Nordisk A/s
-2.8%
32.13%
52.48%
239.51%
414.16%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.96%
10.08%
23.01%
83.3%
130.08%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
2seventy Bio Inc
2seventy Bio Inc
NA
NA
NA
-1.94
-0.77
-0.22
NA
5.04
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.04
26.04
1.46
45.0
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
47.43
47.43
2.4
3.35
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.81
28.81
0.53
16.75
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
2seventy Bio Inc
2seventy Bio Inc
Buy
$219.1M
-87.24%
NA
-216.73%
Moderna, Inc.
Moderna, Inc.
Buy
$41.7B
304.34%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.5B
159.17%
26.04
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$562.8B
414.16%
47.43
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$103.6B
130.08%
28.81
36.68%

Institutional Holdings

  • Goldman Sachs Group Inc

    17.57%

  • Kynam Capital Management, LP

    11.60%

  • Morgan Stanley - Brokerage Accounts

    9.44%

  • Vanguard Group Inc

    7.77%

  • BlackRock Inc

    7.62%

  • Baker Bros Advisors LP

    4.87%

Corporate Announcements

  • 2seventy Bio Inc Earnings

    2seventy Bio Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

we are an immuno-oncology cell therapy company focused on discovering and developing new therapies that truly disrupt the cancer treatment landscape. our name, 2seventy bio, is inspired by the maximum speed of translating human thought into action—270 miles per hour, and at 2seventy, we think in the language of time. with a deep understanding of cancer cell metabolism, genomics, and the human body’s immune response to tumor cells, we’re applying this knowledge and expertise to new classes of cellular therapies that are designed to “think” smarter and faster than cancer. it is this mindset that propels us forward because we know that time matters -- every day, every minute, every second -- to people living with cancer

Organization
2seventy Bio Inc
Employees
274
CEO
Mr. Nick Leschly
Industry
Services

Discover More

FAQs